Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

Biogen Inc. closed 34.53% below its 52-week high of $207.59, which the company achieved on August 21st.

More deals are likely coming down the pipeline for Biogen Inc. as the company looks to build out its early-stage pipeline.

On Friday, BIIB stock gained nearly 3%, bringing its trailing-five-day return to more than 5%. In the past month, BIIB has swung higher to the tune of almost 8%. Interestingly, Friday’s afterhours ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why BIIB stock is a hold.

The Waltham biotech signs more pharma deals than the average company, and already lists Vertex, Takeda and Biogen as its ...

Piper Sandler raised the firm’s price target on Biogen (BIIB) to $118 from $115 and keeps a Neutral rating on the shares. The ...

Biogen (($CC:HTER)) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) is conducting a significant ...

As Biogen’s new CEO Chris Viehbacher pores over Biogen’s books and scouts out M&A deals, he may have one advantage his predecessor didn’t: a good relationship with his board of directors.

Biogen agreed to buy Reata Pharmaceuticals for $7.3 billion, offering the company access to a drug that fits perfectly with its goals of treating both neuromuscular and rare diseases.

Biogen CEO Christopher Viehbacher is embarking on a corporate rethink, one that balances the company's characteristic risky bets with a frank commitment to pragmatism.